Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023
Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
The Company has reported the total number of shares and voting rights as of October 31, 2023. The total number of shares is 96,288,553. The total gross of voting rights is 96,288,553, and the total net of voting rights is 96,084,083.
Positive
- None.
Negative
- None.
Monthly information regarding the total number of voting rights and
total number of shares of the Company as of October 31, 2023
(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)
Market : NYSE Euronext Paris
ISIN Code: FR 0010417345
| Date | Total number of shares | Total number of voting rights |
| 10/31/2023 | 96,288,553 | Total gross of voting rights: 96,288,553 |
| Total net* of voting rights: 96,084,083 |
* Net total = total number of voting rights attached to shares – shares without voting rights
Attachment
FAQ
What is the total number of shares reported by the Company?
The Company has reported a total of 96,288,553 shares.
What is the total gross of voting rights?
The total gross of voting rights reported by the Company is 96,288,553.
What is the total net of voting rights?
The total net of voting rights reported by the Company is 96,084,083.
DBV Technologies S.A.
NASDAQ:DBVT
DBVT Rankings
DBVT Latest News
DBVT Stock Data
129.22M
43.83M
19.64%
0.29%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
United States of America
MONTROUGE
About DBVT
dbv technologies is opening up a decisive new approach to the treatment of allergy – a major public health issue that is constantly increasing in prevalence. food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. dbv technologies (incorporated in 2002) has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. the viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. the product's clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. dbv technologies is focusing on food allergies (milk and